Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic 
phenotype in non-small cell lung cancer

Bulk, Etmar; Yu, Jun; Hascher, Antje; Koschmieder, Steffen; Wiewrodt, Rainer; Krug, Utz; Timmermann, Bernd; Marra, Alessandro; Hillejan, Ludger; Wiebe, Karsten; Berdel, Wolfgang E.; Schwab, Albrecht; Müller-Tidow, Carsten

doi:10.1371/journal.pone.0044591

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer

MPS-Authors

/persons/resource/persons50598

Timmermann, Bernd
Sequencing (Head: Bernd Timmermann), Scientific Service (Head: Christoph Krukenkamp), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

Bulk.pdf
(Publisher version), 705KB

Supplementary Material (public)

There is no public supplementary material available

Citation

Bulk, E., Yu, J., Hascher, A., Koschmieder, S., Wiewrodt, R., Krug, U., et al. (2012). Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer. PLoS One, 7(12): e44591. doi:10.1371/journal.pone.0044591.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0028-E6EA-6

Abstract

Alterations of Eph receptor tyrosine kinases are frequent events in human cancers. Genetic variations of EPHB6 have been described but the functional outcome of these alterations is unknown. The current study was conducted to screen for the occurrence and to identify functional consequences of EPHB6 mutations in non-small cell lung cancer. Here, we sequenced the entire coding region of EPHB6 in 80 non-small cell lung cancer patients and 3 tumor cell lines. Three potentially relevant mutations were identified in primary patient samples of NSCLC patients (3.8%). Two point mutations led to instable proteins. An in frame deletion mutation (del915-917) showed enhanced migration and accelerated wound healing in vitro. Furthermore, the del915-917 mutation increased the metastatic capability of NSCLC cells in an in vivo mouse model. Our results suggest that EPHB6 mutations promote metastasis in a subset of patients with non-small cell lung cancer.